Epigenetics meets genetics in acute myeloid leukemia: Clinical impact of a novel seven-gene score

Journal of Clinical Oncology

Volumn 32, Issue 6, 2014, Pages 548-556

  Marcucci, Guido ^a   Yan, Pearlly ^a   Maharry, Kati ^a,c   Frankhouser, David ^a   Nicolet, Deedra ^a,c   Metzeler, Klaus H ^a   Kohlschmidt, Jessica ^a,c   Mrózek, Krzysztof ^a   Wu, Yue Zhong ^a   Bucci, Donna ^a   Curfman, John P ^a   Whitman, Susan P ^a   Eisfeld, Ann Kathrin ^a   Mendler, Jason H ^a   Schwind, Sebastian ^a   Becker, Heiko ^a   Bär, Constance ^k   Carroll, Andrew J ^d   Baer, Maria R ^e   Wetzler, Meir ^f   Carter, Thomas H ^h   Powell, Bayard L ⁱ   Kolitz, Jonathan E ^g   Byrd, John C ^a   Plass, Christoph ^k   Garzon, Ramiro ^a   Caligiuri, Michael A ^a   Stone, Richard M ^j   Volinia, Stefano ^a   Bundschuh, Ralf ^b   Bloomfield, Clara D ^a   more..

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UNIVERSITY OF MARYLAND   (United States)

^f ROSWELL PARK CANCER INSTITUTE   (United States)

^g North Shore Long Island Center for Advanced Medicine   (United States)

^h UNIVERSITY OF IOWA   (United States)

ⁱ WAKE FOREST SCHOOL OF MEDICINE   (United States)

^j DANA FARBER CANCER INSTITUTE   (United States)

^k GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AXSL1 PROTEIN; CD34 ANTIGEN; CEBPA PROTEIN; CYTARABINE; DAUNORUBICIN; DNA METHYLTRANSFERASE 3A; F2RL1 PROTEIN; FAM92A1 PROTEIN; FLT3 LIGAND; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; MIR155HG PROTEIN; NUCLEOPHOSMIN; RHOC PROTEIN; SCRN1 PROTEIN; TET2 PROTEIN; TRANSCRIPTION FACTOR RUNX1; TUMOR MARKER; UNCLASSIFIED DRUG; VWA8 PROTEIN; WT1 PROTEIN; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GENETICS; CANCER PROGNOSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA METHYLATION; EPIGENETICS; FEMALE; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; SCORING SYSTEM; SEQUENCE ANALYSIS; TUMOR GENE; AGED; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; MIDDLE AGED; MUTATION; PREDICTIVE VALUE; PROGNOSIS; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DAUNORUBICIN; DISEASE-FREE SURVIVAL; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MUTATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 84898679051     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.50.6337     Document Type: Article

References (38)

1. Estey E: AML in older patients: Are we making progress? Best Pract Res Clin Haematol 22:529-536, 2009
2. Dombret H: Gene mutation and AML pathogenesis. Blood 118:5366-5367, 2011
3. Marcucci G, Haferlach T, Döhner H: Molecular genetics of adult acute myeloid leukemia: Prognostic and therapeutic implications. J Clin Oncol 29:475-486, 2011
4. Mrózek K, Marcucci G, Nicolet D, et al: Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol 30:4515-4523, 2012
5. Plass C, Oakes C, Blum W, et al: Epigenetics in acute myeloid leukemia. Semin Oncol 35:378-387, 2008
6. Blum W, Garzon R, Klisovic RB, et al: Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A 107:7473-7478, 2010
7. Figueroa ME, Lugthart S, Li Y, et al: DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 17:13-27, 2010
8. Cancer Genome Atlas Research Network: Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 368: 2059-2074, 2013
9. Deneberg S, Guardiola P, Lennartsson A, et al: Prognostic DNA methylation patterns in cytogenetically normal acute myeloid leukemia are predefined by stem cell chromatin marks. Blood 118:5573-5582, 2011
10. Yan P, Frankhouser D, Murphy M, et al: Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia. Blood 120:2466-2474, 2012
11. Metzeler KH, Hummel M, Bloomfield CD, et al: An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood 112:4193-4201, 2008
12. Mendler JH, Maharry K, Radmacher MD, et al: RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and microRNA expression signatures. J Clin Oncol 30:3109-3118, 2012
13. Gu H, Smith ZD, Bock C, et al: Preparation of reduced representation bisulfite sequencing libraries for genome-scale DNA methylation profiling. Nat Protoc 6:468-481, 2011
14. Claus R, Hackanson B, Poetsch AR, et al: Quantitative analyses of DAPK1 methylation in AML and MDS. Int J Cancer 131:E138-E142, 2012
15. Roh T-Y, Cuddapah S, Zhao K: Active chromatin domains are defined by acetylation islands revealed by genome-wide mapping. Genes Dev 19:542-552, 2005 (Pubitemid 40314987)
16. Riethman H, Ambrosini A, Paul S: Human subtelomere structure and variation. Chromosome Res 13:505-515, 2005 (Pubitemid 41205633)
17. Deaton AM, Bird A: CpG islands and the regulation of transcription. Genes Dev 25:1010-1022, 2011
18. Jones PA: Functions of DNA methylation: Islands, start sites, gene bodies and beyond. Nat Rev Genet 13:484-492, 2012
19. Baylin SB, Chen WY: Aberrant gene silencing in tumor progression: Implications for control of cancer. Cold Spring Harb Symp Quant Biol 70:427-433, 2005 (Pubitemid 44124898)
20. Baer C, Claus R, Frenzel LP, et al: Extensive promoter DNA hypermethylation and hypomethylation is associated with aberrant microRNA expression in chronic lymphocytic leukemia. Cancer Res 72:3775-3785, 2012
21. Brenet F, Moh M, Funk P, et al: DNA methylation of the rst exon is tightly linked to transcriptional silencing. PLoS One 6:e14524, 2011
22. Suzuki H, Maruyama R, Yamamoto E, et al: DNA methylation and microRNA dysregulation in cancer. Mol Oncol 6:567-578, 2012
23. Burnham KP, Anderson DR: Multimodel inference: Understanding AIC and BIC in model selection. Sociol Methods Res 33:261-304, 2004 (Pubitemid 39519124)
24. Raspadori D, Lauria F, Ventura MA, et al: Incidence and prognostic relevance of CD34 expression in acute myeloblastic leukemia: Analysis of 141 cases. Leuk Res 21:603-607, 1997 (Pubitemid 27410023)
25. Karlsson R, Pedersen ED, Wang Z, et al: Rho GTPase function in tumorigenesis. Biochim Biophys Acta 1796:91-98, 2009
26. Miyoshi N, Ishii H, Mimori K, et al: SCRN1 is a novel marker for prognosis in colorectal cancer. J Surg Oncol 101:156-159, 2010
27. Han N, Jin K, He K, et al: Protease-activated receptors in cancer: A systematic review. Oncol Lett 2:599-608, 2011
28. Liang S, Gong F, Zhao X, et al: Prokaryotic expression, purification of a new tumor-relative protein FAM92A1-289 and its characterization in renal cell carcinoma. Cancer Lett 276:81-87, 2009
29. Marcucci G, Maharry KS, Metzeler KH, et al: Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. J Clin Oncol 31:2086-2093, 2013
30. Anney R, Klei L, Pinto D, et al: A genome-wide scan for common alleles affecting risk for autism. Hum Mol Genet 19:4072-4082, 2010
31. Eppert K, Takenaka K, Lechman ER, et al: Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med 17:1086-1093, 2011
32. Li Z, Herold T, He C, et al: Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: An international collaborative study. J Clin Oncol 31:1172-1181, 2013
33. Becker H, Marcucci G, Maharry K, et al: Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: A Cancer and Leukemia Group B study. J Clin Oncol 28:596-604, 2010
34. Figueroa ME, Abdel-Wahab O, Lu C, et al: Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18:553-567, 2010
35. Shih AH, Abdel-Wahab O, Patel JP, et al: The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer 12:599-612, 2012
36. Ley TJ, Ding L, Walter MJ, et al: DNMT3A mutations in acute myeloid leukemia. N Engl J Med 363:2424-2433, 2010
37. Marcucci G, Metzeler KH, Schwind S, et al: Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol 30:742-750, 2012
38. Paik S: Is gene array testing to be considered routine now? Breast 20:S87-S91, 2011 (suppl 3)